293 related articles for article (PubMed ID: 12702725)
1. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity.
Kusu N; Laurikkala J; Imanishi M; Usui H; Konishi M; Miyake A; Thesleff I; Itoh N
J Biol Chem; 2003 Jun; 278(26):24113-7. PubMed ID: 12702725
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
3. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
4. Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot.
Laurikkala J; Kassai Y; Pakkasjärvi L; Thesleff I; Itoh N
Dev Biol; 2003 Dec; 264(1):91-105. PubMed ID: 14623234
[TBL] [Abstract][Full Text] [Related]
5. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways.
Krause C; Korchynskyi O; de Rooij K; Weidauer SE; de Gorter DJ; van Bezooijen RL; Hatsell S; Economides AN; Mueller TD; Löwik CW; ten Dijke P
J Biol Chem; 2010 Dec; 285(53):41614-26. PubMed ID: 20952383
[TBL] [Abstract][Full Text] [Related]
6. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
[TBL] [Abstract][Full Text] [Related]
7. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis.
Ohyama Y; Nifuji A; Maeda Y; Amagasa T; Noda M
Endocrinology; 2004 Oct; 145(10):4685-92. PubMed ID: 15217980
[TBL] [Abstract][Full Text] [Related]
8. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
9. Brorin, a novel secreted bone morphogenetic protein antagonist, promotes neurogenesis in mouse neural precursor cells.
Koike N; Kassai Y; Kouta Y; Miwa H; Konishi M; Itoh N
J Biol Chem; 2007 May; 282(21):15843-50. PubMed ID: 17400546
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
van Bezooijen RL; Roelen BA; Visser A; van der Wee-Pals L; de Wilt E; Karperien M; Hamersma H; Papapoulos SE; ten Dijke P; Löwik CW
J Exp Med; 2004 Mar; 199(6):805-14. PubMed ID: 15024046
[TBL] [Abstract][Full Text] [Related]
11. Estrogen Modulates Bone Morphogenetic Protein-Induced Sclerostin Expression Through the Wnt Signaling Pathway.
Kim RY; Yang HJ; Song YM; Kim IS; Hwang SJ
Tissue Eng Part A; 2015 Jul; 21(13-14):2076-88. PubMed ID: 25837159
[TBL] [Abstract][Full Text] [Related]
12. The role of BMPs in bone anabolism and their potential targets SOST and DKK1.
Kamiya N
Curr Mol Pharmacol; 2012 Jun; 5(2):153-63. PubMed ID: 21787290
[TBL] [Abstract][Full Text] [Related]
13. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex.
Winkler DG; Yu C; Geoghegan JC; Ojala EW; Skonier JE; Shpektor D; Sutherland MK; Latham JA
J Biol Chem; 2004 Aug; 279(35):36293-8. PubMed ID: 15199066
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins.
Winkler DG; Sutherland MS; Ojala E; Turcott E; Geoghegan JC; Shpektor D; Skonier JE; Yu C; Latham JA
J Biol Chem; 2005 Jan; 280(4):2498-502. PubMed ID: 15545262
[TBL] [Abstract][Full Text] [Related]
16. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
[TBL] [Abstract][Full Text] [Related]
17. Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP6 in bone formation.
Kugimiya F; Kawaguchi H; Kamekura S; Chikuda H; Ohba S; Yano F; Ogata N; Katagiri T; Harada Y; Azuma Y; Nakamura K; Chung UI
J Biol Chem; 2005 Oct; 280(42):35704-12. PubMed ID: 16109715
[TBL] [Abstract][Full Text] [Related]
18. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
19. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of bone remodeling occurring in musculoskeletal tumors.
Nakajima K; Kidani T; Miura H
J Orthop Res; 2021 Jul; 39(7):1402-1410. PubMed ID: 33034913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
